Cellectar BioSciences, Inc.
(NASDAQ : CLRB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
ARRYArray BioPharma Inc.
0.01%46.438.1%$738.67m
AMGNAmgen Inc.
0.42%176.861.3%$505.72m
CELGCelgene Corporation
0.10%91.851.3%$444.63m
GILDGilead Sciences, Inc.
-1.69%66.920.9%$404.52m
BIIBBiogen Inc.
-0.31%232.891.3%$386.46m
ILMNIllumina, Inc.
0.37%303.423.5%$337.03m
REGNRegeneron Pharmaceuticals, Inc.
-0.01%298.172.6%$278.13m
SRPTSarepta Therapeutics, Inc.
-2.11%153.6014.7%$204.46m
ALXNAlexion Pharmaceuticals, Inc.
0.63%123.822.0%$199.41m
VRTXVertex Pharmaceuticals Incorporated
0.17%176.671.9%$187.80m
EXASExact Sciences Corporation
-0.87%115.1824.1%$139.27m
AAgilent Technologies, Inc.
-0.84%69.961.6%$134.13m
INCYIncyte Corporation
-1.49%80.182.5%$114.37m
BLUEBluebird Bio, Inc.
-1.27%134.0314.3%$97.95m
BMRNBioMarin Pharmaceutical Inc.
-2.14%82.194.3%$87.44m

Company Profile

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma; CLR 125, which intends to treat micro metastatic disease; CLR 124 which could detects tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded in June,1996 and is headquartered in Florham Park, NJ.